Novo Nordisk Receives FDA Warning on 2025 Plainsboro Inspection - Global Banking & Finance Review
Novo Nordisk received an FDA Warning Letter following a 2025 inspection of its Plainsboro facility, citing cGMP violations. This signals heightened FDA scrutiny on manufacturing quality and may lead to enforcement actions against other firms with similar deficiencies.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; FDA may accelerate inspections and enforcement actions.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a Warning Letter to Novo Nordisk for cGMP violations at its Plainsboro facility, indicating increased enforcement focus on manufacturing compliance.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities
What you must do
Review and strengthen cGMP compliance programs, especially for facilities with recent inspection observations or pending FDA reviews.
Deadline
Immediately; FDA may accelerate inspections and enforcement actions.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)